Grand Life Sciences Group Co., Ltd.

Grand Life Sciences Group Co., Ltd. (hereinafter referred to as "GLS ") is a modern pharmaceutical enterprise group, which integrates R&D, production and sales, and focuses on immunity, infection, severe disease, blood system, digestion and Wound Management, etc. The group has R&D centers and production bases in more than ten cities including Beijing, Chengdu, Hangzhou, Shenyang, Wuhan, Chongqing, Nanjing, Zhengzhou, Yantai, Anshan, etc., and is committed to the research and development of high-end Blood Products, chemical drugs, new recombinant vaccines, nano-targeted preparations, degradable medical devices and high-value raw materials.

In the field of blood products, GLS owns Yuanda Shuyang Pharmaceutical Co., Ltd, one of the top 20 biopharmaceutical companies in China, and the production capacity of its newly built modern factory ranks first in Asia and among the top 10 in the world. The factory not only complies with Chinese GMP standards, but also meets EU and WHO standards. Shuyang products have covered the domestic market and exported to more than 10 countries. In 2021, with the approval of the National Medical Products Administration (NMPA) for the human fibrinogen product, Yuanda Shuyang Pharmaceutical has taken an important step in the field of blood coagulation factors. In the future, it will focus on the development of the full product line of blood products and continue to dig deeper in rare diseases.

In the field of chemical medicine, GLS relies on the four major industrial bases of Grand Life Sciences (Liaoning), Grand Life Sciences (Wuhan), Penglai Nuokang and Liaoning Weibang. The company gives full play to the advantages of large industrial foundation and the raw materials-preparations integration to create nano-target R&D center, enzymatic engineering and polymer material R&D platform, API base and Peruvian snake venom supply base, and is committed to providing original biological drugs, emulsions, high-end preparation products and biodegradable medical devices. Focus on developing perioperative product groups, including Hemostasis, Anesthesia, Analgesia, and anticoagulant drugs. Among them, Hemocoagulase Bothrops Atrox for Injection is the product with the largest share in the domestic hemostatic market, Flurbiprofen Axetil is the first domestically-made targeted analgesic injection, and Collagenase Ointment is currently the only Enzymatic Debridement drug officially approved at home and abroad.

As a well-known pharmaceutical manufacturer in China, Grand Life Sciences (Liaoning) Co., Ltd. aims to provide high-quality and competitive pharmaceuticals to people around the world, including Hemostatic Products, analgesic products, anesthesia products, Nutritional Supplements, etc.